✨ Free AI Report
Grifols, S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Grifols, S.A.
Company Research

Grifols, S.A.: Business Overview, Financials & Competitive Analysis

Grifols operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. As the European leader and third largest worldwide producer of blood plasma–based products, the company also o...

Analyst-debate audio for Grifols, S.A.

AskCyborg analysts argue the bull and bear cases for Grifols, S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Strong operational execution and revenue growth offset by elevated debt levels and refinancing risks create a balanced...

Read the full analyst-debate transcript →
Industry Specialty Biopharmaceuticals / Plasma Therapeutics
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Grifols, S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Grifols, S.A. Overview

Pro stress-test →

Grifols operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. As the European leader and third largest worldwide producer of blood plasma–based products, the company also operates in transfusion medicine and clinical diagnostic technologies. The company addresses critical healthcare needs through specialized protein-based therapies.

Strategic Profile

Pro stress-test →

Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. The company's plasma fractionation capacity is currently at 22 million liters per year, with the aim of reaching 26 million by 2026, as part of efforts to meet growing demand for plasma-derived medicines. Strategic positioning centers on expanding production capacity and therapeutic innovation in plasma-derived solutions.

Competitive Landscape

Pro stress-test →

United Therapeutics, BioMarin Pharmaceutical, Taibang Biological Group, Alnylam Pharmaceuticals, and CSL Behring are among Grifols' competitors. Grifols maintains a competitive edge as the dominant European and third-largest global plasma-derived medicine manufacturer, though it faces emerging competitive threats particularly in select therapeutic areas.

Industry Context

Grifols, S.A. operates in Specialty Biopharmaceuticals / Plasma Therapeutics.

Key facts

Founded: 1909 · Headquarters: Barcelona, Spain · Employees: 23,800 · Revenue: $7.52B · Market cap: $7.9B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Grifols, S.A..

  • Record revenue and profitability in 2025 with improving operational execution amid ongoing deleveraging efforts
  • Plasma capacity expansion targeting 26 million liters annually by 2026 to capture growing demand for plasma-derived therapies
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026FDA approval secured for Fesilty product launch in US during first half of 2026
  • January 2026Board restructure with changes to secretary and vice-secretary roles to improve governance
  • +2 moreTrack every material event for Grifols, S.A. as it happens. Explore monitoring →
Get alerted when Grifols, S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CSL BehringGlobal plasma-derived biotherapeutics manufacturer→BioMarinSpecialized biopharmaceuticals for rare genetic diseases→United TherapeuticsSpecialty biopharmaceutical company for critical care→AlnylamRNAi therapeutics for genetic diseases→

Compare Grifols, S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Grifols, S.A. operates in Specialty Biopharmaceuticals / Plasma Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Biopharmaceuticals / Plasma Therapeutics research →
NEW · MCP server

Ask your AI assistant about Grifols, S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Grifols, S.A. and its top competitor on Cyborg Score”
“What did Grifols, S.A. do this quarter?”
“Is Grifols, S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Grifols, S.A. do?+
Grifols operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. As the European leader and third largest worldwide producer of blood plasma–based products, the company also o...
What is Grifols, S.A.'s Cyborg Score?+
Grifols, S.A. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Grifols, S.A.'s main competitors?+
Named competitors include CSL Behring, BioMarin, United Therapeutics, Alnylam. The full competitive landscape is in the AskCyborg report.
How can I get the full Grifols, S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Grifols, S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Grifols, S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Grifols, S.A.